Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.

Yamout, Bassem I; Zeineddine, Maya M; Tamim, Hani; Khoury, Samia J

Yamout, Bassem I; Zeineddine, Maya M; Tamim, Hani; Khoury, Samia J.

Afiliação

Yamout BI; Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
Zeineddine MM; Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
Tamim H; Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon.
Khoury SJ; Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: sk88@aub.edu.lb.

J Neuroimmunol ; 289: 93-7, 2015 Dec 15.

Article em En | MEDLINE | ID: mdl-26616877

Assuntos

Cloridrato de Fingolimode/uso terapêutico; Imunossupressores/uso terapêutico; Esclerose Múltipla/tratamento farmacológico; Adulto; Estudos de Coortes; Avaliação da Deficiência; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Oriente Médio/epidemiologia; Esclerose Múltipla/epidemiologia

Palavras-chave

Clinical; Efficacy; Fingolimod; Lebanon; Middle East; Multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Imunossupressores / Esclerose Múltipla Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: J Neuroimmunol Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Líbano

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google